PrEP and travel
PrEP and travel PrEP can play an important role in preventing HIV infection in people travelling outside of Australia, along with other measures to reduce HIV and STIs 30. If a patient wants to take daily PrEP while on an overseas trip, they can commence two tablets on the day of departure and cease PrEP […]
PEP use and PrEP
If a person is not taking PrEP but presents within 72 hours of a potential HIV exposure, they should be assessed for non-occupational post-exposure prophylaxis (nPEP) as a matter of urgency and should be offered nPEP immediately according to current nPEP guidelines if appropriate if HIV acquisition risk is likely to continue into the future, PrEP should be […]
Discontinuing daily PrEP in cis men
Clinicians should regularly advise people using PrEP about how to discontinue PrEP. The need for PrEP may end when a partner with HIV achieves sustained HIV viral suppression after at least 6 months of antiretroviral therapy, when a patient enters a mutually monogamous relationship with a seroconcordant partner, or when other social circumstances change. Discontinuing […]
Recommencing PrEP
Clinicians should advise any patient who has discontinued PrEP on how to safely recommence PrEP. Clinicians should advise that if and when a patient decides to recommence PrEP that they must first have repeat HIV testing in case they have acquired HIV infection during the time that they were not taking PrEP. All other baseline clinical and laboratory […]
References
Australasian Sexual Health Alliance (ASHA). Australian STI management guidelines for use in primary care[internet]. Taking a sexual history and contact Updated December 2018. Available at: http:// www.sti.guidelines.org.au/resources/how-to-take-a-sexual-history#how-to-take-a-sexual-history (lastaccessed 3 September 2019). Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch Transgender women in clinicaltrials of pre-exposure prophylaxis.J Acquir Immune Defic Syndr 2016;72 Suppl 3:S226-9. Grant […]
PrEP suitability criteria for people who inject drugs
In the first instance, people who inject drugs (PWID) should be advised of and provided with options for using sterile needles, syringes and other injecting equipment, and offered opioid substitution therapy for those who use opioids. People who inject drugs can be referred to local needle and syringe programs, or the Australian Injecting and Illicit Drug […]
PrEP suitability criteria for heterosexuals
This section addresses PrEP suitability for heterosexuals. This section is relevant to the following populations: (i) people who were assigned female at birth (cis-female), identify as female and as heterosexual; (ii) people who were assigned male at birth (cis-male), identify as male and identify as heterosexual; (iii) people who were assigned male at birth (cis-male), […]
PrEP suitability criteria for men who have sex with men
This section addresses PrEP suitability for MSM. This section is relevant to people who were assigned male at birth and identify as male, known as cis-men. This section is also relevant to people who were assigned female at birth but identify as male, known as trans-men. Of note, trans-men who have sex with men may […]
Suitability for PrEP – Parallel of Chapter 4
The guidance on PrEP suitability in this chapter is identical to the guidance provided in Chapter 4 on PrEP suitability. However this chapter is written for clinicians who prefer to and are skilled in evaluating people’s suitability for PrEP according to how the person reports their gender identity and sexuality. For example a person assigned […]
References
Fonner VA, Dalglish SL, Kennedy CE, et Effectiveness and safety of oral HIV preexposure prophylaxis forall populations. AIDS 2016; 30:1973-83. Haberer Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routinepractice. Curr Opin HIV AIDS 2016;11:10-7. Van Damme L, Corneli A, Ahmed K, et Preexposure prophylaxis for HIV infection among African […]